What is CDTX's current stock price?

As of now, CDTX is trading at $101.52, with a daily change of -0.41%.

What are the risks associated with CDTX stock?

CDTX Key risk is its Moderate Risk Level, .

What is CDTX next earnings date?

CDTX next earnings report is scheduled for Nov 6, 2025.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Earnings Calendar Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

CDTX Stock Analysis & IQ Rating | Cidara Therapeutics Inc.

CDTX SYMBOL Badge

Cidara Therapeutics Inc.

$101.52

-$0.50 | -0.41%

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Headlines

52W High

$ 121.21

MKT CAP

$ 2.60B

52W Low

$ 10.37

VOL

$ 562.61K

P/E Ratio

N/A

AVG VOL

$ 1.12M

RSI

58.65

TREND

Uptrend

CDTX Stock IQ

Login to see Cidara Therapeutics Inc. (CDTX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

CDTX Target Price

Login to display

Strengths

CDTX Rewards

Upgraded on attractively valued

CDTX Rewards

Trading below its fair value

CDTX Rewards

Outperform the market

Risk Analysis

CDTX Risk Analysis

Earnings are forecast to decrease

Chart

$73.49 (+38.14%)

$62.68 (+61.97%)

$22.02 (+361.04%)

$13.25 (+666.19%)

1year

6month

3month

1month

CDTX Risk Level

CDTX has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

LOW

HIGH

CDTX Analysts Opinion

CDTX overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

CDTX Analysts Opinion

CDTX Analysts opinion is positive and also has improved from the past 3 months

CDTX Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

92%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

60%

CDTX Street Opinion

CDTX Street view is extremely bullish and have positive views on the near-term outlook

CDTX Performance Sentiment

Sentiments overview associated with CDTX events and the stock performance.

92%

8%

Positive

Negative

23 out of 25
events present

2 out of 25
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$101.52

Resistance
Price

$68.71

Current Price Range

$116.13

Show methods +

CDTX Earnings

The TTM reflects 12-month period, providing review of CDTX financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

1

23

-

Cost of Revenue

-

2

-

Gross Profit

-

62

-

Operating Exp

209

177

50

+104.45%

Operating Inc

-209

-176

-27

-

Net Interest Inc

7

6

2

+87.08%

Interest Inc

-

6

2

-

EPS Growth

-7.75

-26.75

-5.25

-

CDTX Financial Health

The company financial health has shown minor improvement, but significant issues remain

Financial Score

2.86

Next Earnings Date: Nov 6, 2025

CDTX Latest Analysis +

Morgan Stanley Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight Recommendation. Fintel reports that on October 16 2025 Morgan Stanley initiated coverage of Cidara Therapeutics (NasdaqCM:CDTX) with a Overweight recommendation. Analyst Price Forecast Suggests 27.15% Upside

Thu Oct 16, 2025

$102.02 | -3.41%

Rating

Cidara Therapeutics gains overweight rating at Morgan Stanley.

Thu Oct 16, 2025

$102.02 | -3.41%

Rating

FDA Grants Cidara Therapeutics CD388 Breakthrough Therapy Designation for Flu Prevention in High-Risk Patients. Cidara Therapeutics Inc. (NASDAQ:CDTX) is one of the best hot stocks to invest in. On October 9 Cidara Therapeutics announced that the US FDA granted Breakthrough Therapy designation for its drug-Fc conjugate/DFC therapeutic candidate CD388. The designation is for the prevention of influenza A and B in adults and adolescents who are at higher risk [….]

Thu Oct 16, 2025

$102.02 | -3.41%

Activity

Potential

JP Morgan Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight Recommendation. Fintel reports that on October 10 2025 JP Morgan initiated coverage of Cidara Therapeutics (NasdaqCM:CDTX) with a Overweight recommendation. Analyst Price Forecast Suggests 21.25% Upside

Fri Oct 10, 2025

$113.05 | +2.07%

Rating

CDTX Stock Up on FDAs Breakthrough Therapy Tag for CD388 in Influenza. Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.

Fri Oct 10, 2025

$113.05 | +2.07%

Activity

Momentum

Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage. ) shares are trading higher on Friday after the biotech company made a recent announcementabout their presentation at the upcoming ESWI 2025 conference. JP Morgan also initiated coverage of the stock assigning it an Overweight rating and .

Fri Oct 10, 2025

$113.05 | +2.07%

Activity

Momentum

Rating

Cidara Therapeutics Analyst Says Lead Influenza Candidate Is Strategically Attractive. JP Morgan initiated coverage of ) on Friday citing its lead asset CD388 for influenza underscoring the game-changing potential of the product and multi-billion dollar .Analyst Anupam Rama says across doses prevention efficacy was ahead of known vaccine benchmarks across various populations with the highest dose (450mg) showing a prevention efficacy of around 76% with no major safety concerns.In June the compan

Fri Oct 10, 2025

$113.05 | +2.07%

Potential

HC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy Recommendation. Fintel reports that on October 9 2025 HC Wainwright &. Co. maintained coverage of Cidara Therapeutics (NasdaqCM:CDTX) with a Buy recommendation. Analyst Price Forecast Suggests 21.43% Upside

Fri Oct 10, 2025

$113.05 | +2.07%

Rating

WBB Securities Maintains Cidara Therapeutics (CDTX) Strong Buy Recommendation. Fintel reports that on October 9 2025 WBB Securities maintained coverage of Cidara Therapeutics (NasdaqCM:CDTX) with a Strong Buy recommendation. Analyst Price Forecast Suggests 21.43% Upside

Fri Oct 10, 2025

$113.05 | +2.07%

Rating

Why Cidara Therapeutics Stock Crushed It Today. Key PointsIt reported some highly encouraging news about its leading drug candidate.

Thu Oct 9, 2025

$110.76 | +12.44%

Activity

FAQ About CDTX Stock Insights

What is CDTX current stock price?

What are CDTX stock strengths?

What risks are associated with CDTX stock?

When is CDTX next earnings report?

What is CDTX market cap and volume?

What is CDTX's current Stock IQ?

Should I buy CDTX stock right now?

Is CDTX a Strong Buy right now?

What does a 'Strong Buy' rating mean for CDTX?

What does a 'Strong Sell' rating mean for CDTX?

What factors influence CDTX's Stock IQ?

Explore our CDTX Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored CDTX Stock Strategies
Effective Risk Management

FIND US ON

Receive our CDTX Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

CDTX CDTX Badge

Cidara Therapeutics Inc.

Current Price

$101.52

-$0.50 | -0.41%

52W High

$ 121.21

MKT CAP

$ 2.60B

52W Low

$ 10.37

VOL

$ 562.61K

P/E Ratio

N/A

AVG VOL

$ 1.12M

RSI

58.65

TREND

Uptrend

Create Alerts

Overview

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Earnings

Target Price

Login to display

Not Enough Information

Stock Insights

Strengths

CDTX Rewards

Upgraded on attractively valued

CDTX Rewards

Trading below its fair value

CDTX Rewards

Outperform the market

Risk Analysis

CDTX Risk Analysis

Earnings are forecast to decrease

CDTX Stock IQ

Login to unlock Cidara Therapeutics Inc. (CDTX) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Chart

$73.49 (+38.14%)

$62.68 (+61.97%)

$22.02 (+361.04%)

$13.25 (+666.19%)

1year

6month

3month

1month

CDTX Analysts Opinion

CDTX Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
menu Hover over the category for more information

CDTX Analysts Opinion

CDTX Analysts opinion is positive and also has improved from the past 3 months

CDTX Street Consensus

Analysts perspectives on the stock desirability, trend direction, and growth potential.

92%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

100%

60%

CDTX Street Opinion

CDTX Street view is extremely bullish and have positive views on the near-term outlook

CDTX Risk Level

CDTX has Moderate Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

LOW

HIGH

CDTX Performance Sentiment

Sentiments overview associated with CDTX events and the stock performance.

92%

8%

Positive

Negative

23 out of 25
events present

2 out of 25
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels.

Login to display

Support
Price

$101.52

Resistance
Price

$68.71

Current Price Range

$116.13

Show methods +

CDTX Earnings

The TTM data reflects the most recent 12-month period, providing overview of CDTX financial performance.

Millions of Dollars

TTM

2024

2023

CAGR

Total Revenue

1

23

-

Cost of Revenue

-

2

-

Gross Profit

-

62

-

Operating Exp

209

177

50

+104.45%

Operating Inc

-209

-176

-27

-

Net Interest Inc

7

6

2

+87.08%

Interest Inc

-

6

2

-

EPS Growth

-7.75

-26.75

-5.25

-

CDTX Financial Health

The company financial health has shown minor improvement, but significant issues remain

Financial Score

2.86

Next Earnings Date: Nov 6, 2025

CDTX Latest Analysis

Morgan Stanley Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight Recommendation. Fintel reports that on October 16 2025 Morgan Stanley initiated coverage of Cidara Therapeutics (NasdaqCM:CDTX) with a Overweight recommendation. Analyst Price Forecast Suggests 27.15% Upside

Thu Oct 16, 2025

$102.02 | -3.41%

Rating

Cidara Therapeutics gains overweight rating at Morgan Stanley.

Thu Oct 16, 2025

$102.02 | -3.41%

Rating

FDA Grants Cidara Therapeutics CD388 Breakthrough Therapy Designation for Flu Prevention in High-Risk Patients. Cidara Therapeutics Inc. (NASDAQ:CDTX) is one of the best hot stocks to invest in. On October 9 Cidara Therapeutics announced that the US FDA granted Breakthrough Therapy designation for its drug-Fc conjugate/DFC therapeutic candidate CD388. The designation is for the prevention of influenza A and B in adults and adolescents who are at higher risk [….]

Thu Oct 16, 2025

$102.02 | -3.41%

Activity

Potential

JP Morgan Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight Recommendation. Fintel reports that on October 10 2025 JP Morgan initiated coverage of Cidara Therapeutics (NasdaqCM:CDTX) with a Overweight recommendation. Analyst Price Forecast Suggests 21.25% Upside

Fri Oct 10, 2025

$113.05 | +2.07%

Rating

CDTX Stock Up on FDAs Breakthrough Therapy Tag for CD388 in Influenza. Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.

Fri Oct 10, 2025

$113.05 | +2.07%

Activity

Momentum

Cidara Therapeutics Surges Ahead of ESWI 2025 Presentation and JP Morgan Coverage. ) shares are trading higher on Friday after the biotech company made a recent announcementabout their presentation at the upcoming ESWI 2025 conference. JP Morgan also initiated coverage of the stock assigning it an Overweight rating and .

Fri Oct 10, 2025

$113.05 | +2.07%

Activity

Momentum

Rating

Cidara Therapeutics Analyst Says Lead Influenza Candidate Is Strategically Attractive. JP Morgan initiated coverage of ) on Friday citing its lead asset CD388 for influenza underscoring the game-changing potential of the product and multi-billion dollar .Analyst Anupam Rama says across doses prevention efficacy was ahead of known vaccine benchmarks across various populations with the highest dose (450mg) showing a prevention efficacy of around 76% with no major safety concerns.In June the compan

Fri Oct 10, 2025

$113.05 | +2.07%

Potential

HC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy Recommendation. Fintel reports that on October 9 2025 HC Wainwright &. Co. maintained coverage of Cidara Therapeutics (NasdaqCM:CDTX) with a Buy recommendation. Analyst Price Forecast Suggests 21.43% Upside

Fri Oct 10, 2025

$113.05 | +2.07%

Rating

WBB Securities Maintains Cidara Therapeutics (CDTX) Strong Buy Recommendation. Fintel reports that on October 9 2025 WBB Securities maintained coverage of Cidara Therapeutics (NasdaqCM:CDTX) with a Strong Buy recommendation. Analyst Price Forecast Suggests 21.43% Upside

Fri Oct 10, 2025

$113.05 | +2.07%

Rating

Why Cidara Therapeutics Stock Crushed It Today. Key PointsIt reported some highly encouraging news about its leading drug candidate.

Thu Oct 9, 2025

$110.76 | +12.44%

Activity

Discover CDTX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of CDTX. We're here to help you make informed investment decisions today.

FIND US ON

Receive our CDTX Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

CDTX Stock trends

CDTX Stock performance

CDTX Stock analysis

CDTX investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing CDTX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing CDTX

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence, and cutting-edge intelligence.

CDTX Stock Analysis & IQ Rating | Cidara Therapeutics Inc.

CDTX Stock IQ

CDTX Target Price

CDTX Risk Level

CDTX Analysts Opinion

CDTX Street Consensus

CDTX Performance Sentiment

Technical Price Levels

CDTX Financial Health

Explore our CDTX Stock insights

Receive our CDTX Daily Alerts

CDTX Stock IQ

CDTX Street Consensus

CDTX Risk Level

Technical Price Levels

Discover CDTX Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends, and the future potential of CDTX. We're here to help you make informed investment decisions today.

Receive our CDTX Daily Alerts

CDTX Runner Alarm